Dr. Li Discusses the PROFILE Crizotinib Clinical Trials

Video

Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials

Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, discusses the PROFILE clinical trials examining ALK-positive non-small cell lung cancer patients that led to the FDA approval of Pfrizer's crizotinib (Xalkori).

The 1001 trial examined 119 ALK-positive NSCLC patients with a 61% overall response rate and 69% partial response rates. The 1005 trial also exhibited great results, with 136 patients and a 50% overall response rate, including 1 complete response and 67% partial response.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine